Active, not recruitingPhase 3NCT06149403
A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
Studying Hurler syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Orchard Therapeutics
- Intervention
- Experimental: OTL-203(genetic)
- Enrollment
- 41 enrolled
- Eligibility
- All sexes
- Timeline
- 2023 – 2031
Study locations (5)
- University of Minnesota, Pediatrics, Minneapolis, Minnesota, United States
- Ospedale San Raffaele, Milan, Italy
- Princess Maxima Center, Utrecht, Netherlands
- UMC Utrecht, Utrecht, Netherlands
- Manchester University NHS Foundation Trust Blood and Marrow Transplant Programme, Royal Manchester Children's Hospital, Manchester, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06149403 on ClinicalTrials.gov